RITUXIMAB for Pemphigus vulgaris | Pemphigus foliaceus

Inclusion criteria

• {"criterion_text":"- Age ≥ 18 and ≤ 80 years\n- Patient affiliated with, or beneficiary of a social security (national health insurance) plan\n- Signed Informed Consent Form (or from the family in case of impossibility of patient’s consent).\n- Confirmed newly diagnosed PV or PF, based on the presence of the following: histological features of acantholysis on skin or mucosal biopsy, and deposition of IgG, complement component 3, or both on the keratinocyte membrane detected by direct immunofluorescence on affected skin or mucosa\n- Presence of moderate-to-severely active disease, defined by an overall PDAI score> 15\n- Patient able to receive the standard-of-care consisting of corticosteroids (prednisone 1 mg/kg/day PO) and rituximab\n- Patients must be vaccinated against Covid-19 before study entry. It is recommended that patients are vaccinated against influenza and pneumococcus and have their first injection (Prevenar 13 or 20) before study entry.\n- For women who are not postmenopausal (menopausal: ≥ 12 months of non−therapy-induced amenorrhoea) or not sterile: agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, during the treatment period and for at least 12 months after the last dose of study treatment. They must have a negative result from a blood beta-HCG test within 1 week prior to randomization Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Barrier methods must always be supplemented with the use of a spermicide.\n- For men: Surgical sterility or agreement to remain abstinent or use a condom during the treatment period and for at least 12 months after the last dose of study treatment and agreement to refrain from donating sperm during this same period. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n- Able to comply with the study protocol, in the investigator’s judgment"}

Exclusion criteria

• {"criterion_text":"- Non-consenting patient or patient who cannot be followed regularly.\n- Significant cardiovascular or pulmonary disease (including o bstructive pulmonary disease)\n- Uncontrolled concomitant disease that, in the investigator’s judgment, would preclude patient participation, including but not limited to nervous system, renal, hepatic, endocrine, or gastrointestinal disorders\n- Any concomitant condition that required treatment with oral or systemic corticosteroids within 12 weeks prior to randomization- excluding transitory treatments (such as a corticosteroid therapy prescribed for a few days for an acute infection), and chronic corticosteroid treatments with a prednisone / prednisolone dose ≤20 mg/day, (these latter patients remain eligible for study entry)\n- Treatment with IV Ig, plasmapheresis, or other similar procedure (immunoadsorption) within 8 weeks prior to randomization\n- Patients having received immunosuppressive treatment (such as cyclosporine, mycophenolate mofetil, azathioprine given at an effective dose for any other condition than Pemphigus, or any other treatment that might potentially be active on Pemphigus lesions (anti-TNF) within 4 weeks prior to baseline\n- Treatment with cyclophosphamide within 12 weeks prior to randomization\n- Patients with positive blood test for HIV\n- Inherited or acquired severe immune deficiency\n- Severe active infection (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV anti-infectives within 4 weeks prior to screening. Entry into this study may be reconsidered once the infection has fully resolved\n- Patients with a currently treated cancer, including solid tumors, hematologic malignancies, and carcinoma (except basal cell of the skin and squamous cell carcinoma of the skin which are small and localized and can be easily cured with a standard excision )\n- Diagnosis of paraneoplastic pemphigus or other non-PV or PF autoimmune blistering disease\n- Patients with a past history (< 5 years) of cancer, including solid tumors, hematologic malignancies, and carcinoma (except complete excision of basal cell carcinoma and squamous cell carcinoma of the skin that have been excised and cured) NB: Patients whose cancer is cured and do not have anti-cancer treatment anymore must be referred to an oncologist before entry in the study\n- Currently active alcohol or drug abuse, or history of alcohol or drug abuse within 24 weeks prior to screening\n- Major surgery within 4 weeks prior to randomization, excluding diagnostic surgery\n- Treatment with rituximab or a B cell−targeted therapy (e.g., anti-CD20, anti-CD22, or anti-BLyS) within 12 months prior to randomization\n- Treatment with a live or attenuated vaccine within 28 days prior to randomization. It is recommended that a patient’s vaccination record and the need for immunization prior to study entry be carefully investigated.\n- Major biological abnormality which in the investigator’s judgment, would preclude patient participation\n- Positive test results for hepatitis B surface antigen (HBsAg),HBe antigen, positive hepatitis B DNA, or hepatitis C virus(HCV) serology at screening\n- Participation in another interventional clinical trial within 28 days prior to randomization and during the study\n- Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)\n- Contraindication to rituximab marketed as 500 mg concentrate for solution for infusion\n- Contraindication to prednisone marketed as 20 mg scored tablet pharmaceutical form\n- Contraindication to methylprednisolone marketed as 120 mg powder for injectable solution pharmaceutical form\n- Contraindication to paracetamol marketed as 10 mg/mL solution for infusion pharmaceutical form\n- Contraindication to dexchlorpheniramine maleate marketed as 5 mg/1mL injectable solution pharmaceutical form\n- Lack of peripheral venous access\n- Pregnant or lactating women"}

Primary endpoints

• {"endpoint_text":"- Any concomitant condition that required treatment with oral or systemic corticosteroids within 12 weeks prior to randomization- excluding transitory treatments (such as a corticosteroid therapy prescribed for a few days for an acute infection), and chronic corticosteroid treatments with a prednisone / prednisolone dose ≤20 mg/day, (these latter patients remain eligible for study entry)","definition_or_measurement_approach":""}

France

Earliest CTIS Part Ii Submission Date

25-07-2024

Latest Decision Or Authorization Date

23-01-2026

Processing Time Days

547

Number Of Sites

30

Number Of Participants

133

Primary sponsor

Full Name

Centre Hospitalier Universitaire Rouen

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

France